Effects of human salivas on recombinant HIV-1 proteins.
Human saliva appears to contain factors that are inhibitory to HIV-1 infectivity in vitro. We investigated the effect of incubating human whole, parotid, labial minor salivary gland and sublingual/submandibular salivas with recombinant HIV-1 envelope protein (gp160). Saliva/gp160 mixtures were run on polyacrylamide gels, transferred to nitrocellulose, and assayed for the presence of gp160 using monoclonal antibodies or HIV-1-positive sera. Incubation of the gp160 with whole saliva reduced the intensity of gp160 bands to 35% of control values. Minor salivary gland saliva reduced the band intensities to 65% of control values, while other saliva types diminished gp160 to 75% of control values. Protease inhibitors had no effect. Components of untreated whole human saliva prevent the detection of the HIV-1 envelope protein gp160 by antibodies to gp120 and gp41 in immunoblots. The results suggest that complexes between whole saliva factors and certain domains of gp160 block monoclonal antibody binding or are unable to migrate through polyacrylamide gels.
Department of Oral Pathology, University of Maryland Dental School, Baltimore.
D W
DW
Archibald
C A
CA
Hebert
K L
KL
Gregory
G K
GK
Lewis
D015686:Gene Products, env / Q000032:analysis*; D016655:HIV Core Protein p24 / Q000032:analysis*; D019302:HIV Envelope Protein gp160; D015497:HIV-1; D006801:Humans; D010306:Parotid Gland / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D011498:Protein Precursors / Q000032:analysis*; D011994:Recombinant Proteins; D012463:Saliva / Q000502:physiology*; D012470:Salivary Glands, Minor / Q000378:metabolism
D015686:Gene Products, env; D016655:HIV Core Protein p24; D019302:HIV Envelope Protein gp160; D011480:Protease Inhibitors; D011498:Protein Precursors; D011994:Recombinant Proteins